Key Points
- COO Warren Stone sold 22,128 shares of NeoGenomics at an average price of $12.50 on Jan 20 for $276,600, reducing his holding by 15.39% to 121,631 shares, according to an SEC filing.
- NeoGenomics reported $0.03 EPS and $187.8M revenue for the quarter (revenue +12% YoY) but still shows a negative net margin and ROE, and set FY2025 guidance of 0.080–0.120 EPS.
- NEO trades near $12.69 with a 52-week range of $4.72–$15.32 and a $1.64B market cap; analysts are mixed (average target ~$12) and the stock has a negative price-to-earnings ratio.
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) COO Warren Stone sold 22,128 shares of NeoGenomics stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total transaction of $276,600.00. Following the completion of the sale, the chief operating officer owned 121,631 shares in the company, valued at approximately $1,520,387.50. This represents a 15.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
NeoGenomics Price Performance
NASDAQ NEO opened at $12.69 on Thursday. The company has a 50-day moving average price of $11.98 and a two-hundred day moving average price of $9.36. NeoGenomics, Inc. has a 52 week low of $4.72 and a 52 week high of $15.32. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -14.42 and a beta of 1.58. The company has a current ratio of 3.91, a quick ratio of 3.62 and a debt-to-equity ratio of 0.41.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.01. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.The business had revenue of $187.80 million during the quarter, compared to the consensus estimate of $183.85 million. During the same period in the previous year, the firm posted $0.05 earnings per share. The business's revenue was up 12.0% on a year-over-year basis. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages have recently commented on NEO. Needham & Company LLC restated a "buy" rating and set a $14.00 price objective on shares of NeoGenomics in a research note on Monday, January 12th. Zacks Research raised shares of NeoGenomics from a "hold" rating to a "strong-buy" rating in a research note on Monday, January 12th. Leerink Partners set a $14.00 price target on shares of NeoGenomics in a research note on Tuesday, October 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of NeoGenomics in a research note on Monday, December 29th. Finally, TD Cowen reissued a "buy" rating on shares of NeoGenomics in a report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, NeoGenomics has an average rating of "Hold" and an average target price of $12.00.
Check Out Our Latest Stock Analysis on NEO
Hedge Funds Weigh In On NeoGenomics
Several hedge funds have recently made changes to their positions in NEO. Aster Capital Management DIFC Ltd lifted its stake in NeoGenomics by 42.5% during the third quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company's stock valued at $26,000 after purchasing an additional 997 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of NeoGenomics in the second quarter valued at $32,000. GAMMA Investing LLC lifted its position in shares of NeoGenomics by 68.2% during the 4th quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company's stock valued at $42,000 after acquiring an additional 1,460 shares during the last quarter. Capstone Financial Advisors Inc. bought a new stake in shares of NeoGenomics during the 2nd quarter worth $73,000. Finally, Captrust Financial Advisors acquired a new position in shares of NeoGenomics in the 2nd quarter worth $75,000. Institutional investors and hedge funds own 98.50% of the company's stock.
About NeoGenomics
(
Get Free Report)
NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.
The company's core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
